Riskpilot← Back to searchSign inGet full accessAllergenius AB
ABDissolvedOrg 5594523176Manufacture of soap and detergents, cleaning and polishing preparations · NACE 2041Est. 20230 employees
Revenue 2024
SEK 729K
EBITDA margin
-8.2%
Equity ratio
17.3%
Financial strength
Net profit 2024
SEK -61K
0 employees
| Revenue | SEK 729K | — |
| EBITDA | SEK -60K | — |
| Net profit | SEK -61K | — |
| Total assets | SEK 950K | — |
| Equity | SEK 164K | — |
| Employees | 0 | — |
Legal name
Allergenius AB
Org number
5594523176
Legal form
Aktiebolag
NACE code
2041 · Manufacture of soap and detergents, cleaning and polishing preparations
Founded
12 oktober 2023
Share capital
SEK 25 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska idka handel med, distribution och försäljning av sjukvårds- och läkemedelsprodukter för hälso-, sjuk- och friskvård samt apotek i Sverige och övriga Europa. Vidare skall bolaget bedriva konsultverksamhet inom läkemedelsbranschen.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2024 |
|---|---|
| Revenue | 729 |
| Staff expenses | — |
| EBITDA | −60 |
| Depreciation & amort. | — |
| EBIT | −60 |
| Net financials | −1 |
| Profit before tax | −61 |
| Tax | — |
| Net profit | −61 |
| Item | 2024 |
|---|---|
| Total assets | 950 |
| Equity | 164 |
| Long-term debt | — |
| Short-term debt | 785 |
| Total debt | 785 |
EBITDA margin
-8.2%
This company
15.8%
Market median
-152% vs market
20242024
Equity ratio
17.3%
This company
38.2%
Market median
-55% vs market
20242024
Return on equity
-37.0%
This company
18.4%
Market median
-301% vs market
20242024
Net profit margin
-8.3%
This company
8.1%
Market median
-202% vs market
20242024
Asset turnover
0.77×
This company
1.12×
Market median
-31% vs market
20242024
Debt / equity
4.78×
This company
0.62×
Market median
-671% vs market
20242024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-10-12 – 2024-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RK Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2024 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Board of Directors | 2024 | — | — | |
| Deputy Board Member | 2023 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Addeira Pharmaceuticals AB | Company | 100.0% | 100.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Addeira Holding AB
Allergenius AB Board members of Allergenius AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Robert Karl-Axel Anthony Svanström | Chief Executive Officer | 0 companies |
| Hans Anders Conrad Grönlund | Deputy Board Member | 0 companies |
| Stina Maria Selldén | Deputy Board Member | 0 companies |
| Malkolm James Makdesi Elias | Board of Directors | 0 companies |
| Erik Alexander Stötsberg | Deputy Board Member | 0 companies |
| Bo Carl Magnus Karlstedt | Board of Directors | 0 companies |
| Karl Anders Torell | Chairman | 0 companies |
| Mikaela Jenni Berglund | Board of Directors | 0 companies |